Abstract 4535: JAB-26766: A small-molecule, orally bioavailable PARP7 inhibitor with high potency and selectivity

Abstract Background: PARP7 (also referred to as TIPARP or ARTD14) is a mono-ADP-ribosyl transferase that inhibits type I interferon (IFN) signaling. Targeting PARP7 to restore antitumor immunity represents a promising treatment strategy. We have developed JAB-26766, an orally bioavailable, highly potent, and selective PARP7 inhibitor. Methods: A time-resolved fluorescence energy transfer (TR-FRET) assay was applied to determine the binding and inhibition of PARP7 by JAB-26766. IFN-β secretion assay, STAT1 phosphorylation assay, and ISG (interferon stimulated gene) mRNA assay were performed to evaluate the inhibitory activities of JAB-26766 on the downstream signaling of PARP7. CellTiter-Glo assay was performed to evaluate cell viability upon treatment of JAB-26766. In vivo PK-PD study was conducted to evaluate the relationship between JAB-26766 concentration and the level of tumor STAT1 phosphorylation. The antitumor activity of JAB-26766 either as a single agent or in different drug combinations was evaluated in multiple mouse models. Results: High potency of JAB-26766 on PARP7 inhibition as well as 1800-fold selectivity over PARP2 was observed through biochemical assays. At the cellular level, JAB-26766 induced IFN-β secretion, up-regulated ISG mRNA levels, increased phosphorylation of STAT1, and inhibited cell viability of multiple tumor cell lines (with most IC50 values below 50 nM). JAB-26766 combined with a STING agonist resulted in synergistic activation of STING pathway, as evidenced by increased CXCL10 secretion, and inhibited tumor cell proliferation. In vivo PK-PD study showed that JAB-26766 exposure in plasma and tumor has good correlation with induction of tumor STAT1 phosphorylation. Furthermore, JAB-26766 showed potent antitumor activity and good tolerability either as monotherapy or combined with STING agonist or anti-PD-1 antibody in mouse models of non-small cell lung cancer, breast cancer and colorectal cancer. Conclusions: JAB-26766 is an orally bioavailable, highly potent, and selective PARP7 inhibitor that shows early promising anti-tumor activities. Citation Format: Di Kang, Yanping Wang, Xin Sun, Man Yan, Haijun Li, Mingming Chen, Yiwei Lin, Wei Long. JAB-26766: A small-molecule, orally bioavailable PARP7 inhibitor with high potency and selectivity abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts) ; 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84 (6Suppl): Abstract nr 4535.